Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash from Operations (2022 - 2025)

Historic Cash from Operations for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$18.8 million.

  • BioXcel Therapeutics' Cash from Operations fell 1498.96% to -$18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.2 million, marking a year-over-year increase of 3076.44%. This contributed to the annual value of -$72.0 million for FY2024, which is 5353.28% up from last year.
  • As of Q3 2025, BioXcel Therapeutics' Cash from Operations stood at -$18.8 million, which was down 1498.96% from -$12.6 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Cash from Operations high stood at -$12.0 million for Q1 2025, and its period low was -$52.4 million during Q1 2023.
  • Moreover, its 4-year median value for Cash from Operations was -$26.9 million (2023), whereas its average is -$27.1 million.
  • In the last 5 years, BioXcel Therapeutics' Cash from Operations plummeted by 6151.85% in 2023 and then surged by 6617.96% in 2024.
  • Over the past 4 years, BioXcel Therapeutics' Cash from Operations (Quarter) stood at -$38.6 million in 2022, then surged by 30.48% to -$26.9 million in 2023, then soared by 44.87% to -$14.8 million in 2024, then dropped by 26.86% to -$18.8 million in 2025.
  • Its Cash from Operations stands at -$18.8 million for Q3 2025, versus -$12.6 million for Q2 2025 and -$12.0 million for Q1 2025.